$FRLF Ok did some initial DD and threw the following together...please let me know if you see any issues/incorrect items.
On Business Lines, ideally I would like to fill in a revenue potential for each...I have the $2.8m for Tierra, and the company estimated $400k for the quarter ending 6/30 in its 3/31 PR (I assume this didn’t factor in Tierra), so conservatively that’s $1.6m/year from all other business lines (BUT I recall someone sharing some crop harvest revenue projections of like $4m but now I can’t find it...please help)...so from known numbers I see $4.4m revenue potential (and maybe another $4m when I confirm that crop harvest)...now we start to see a scenario where the valuation is $20m but we’re on the doorstep of $8m in annual revenue...this is about the ratio (valuation of 2x annualized current revenue that I found myself in on P*TN back in October 2017 when I bought in at .06 and rode it to $1).
Do folks in the know agree with my logic here or am I missing something? Any other good info to add to the below?
FRLF INITIAL DD SUMMARY:
1) Key Shareholders
a. Clifford Perry (CEO, CFO, Director) = 48% of common stock
b. Richard Groberg (CFO) = 1.4m shares
c. Ray Medeiros (Director) = 2.7m shares
d. Paul Pelosi (Board Chair) = 5.1m shares
2) Business Lines — vertically integrated media and CBD product company
a. LaMarihuana.com and Marihuana-Medicinal.com — April 2017, Spanish speaking web portals
b. Leafceuticals Inc — began ops Jan 2018, hemp extraction business
c. Freedom Leaf International Inc. — no active operations
d. Irie CBD — hemp CBD product line
e. Hempology —CBD health/wellness brand
f. Valencia, Spain — hemp greenhouse
g. Plants to Paper — rolling paper company
h. Freedom Leaf Magazine — flagship publication
i. Tierra Science Global, LLC - 8/1/18, health supplements, $500k rev in 1st half of 2018 (manufacturing done by Irie) - est annual rev of $2.88m and 24% profit margin
j. Healthy Discovery Associates Corp - nutraceutical LDL Cholesterol inhibitor intellectual property acquisition
k. Green Market Europe - purchase that was cancelled on 6/4/18
3) Preferred Shares = 10m authorized, 1m is Series A convertible into 100 common per share
4) Revenues & Exp -
a. Reduction vs. 2017 is from moving away from licensing to product sales
b. $50k 3/31 quarter revenue from $30k CBD oil, $20k sale of product
c. Growth in G&A expense attributable in part to stock based compensation, non-cash expense
Amac1001
On Business Lines, ideally I would like to fill in a revenue potential for each...I have the $2.8m for Tierra, and the company estimated $400k for the quarter ending 6/30 in its 3/31 PR (I assume this didn’t factor in Tierra), so conservatively that’s $1.6m/year from all other business lines (BUT I recall someone sharing some crop harvest revenue projections of like $4m but now I can’t find it...please help)...so from known numbers I see $4.4m revenue potential (and maybe another $4m when I confirm that crop harvest)...now we start to see a scenario where the valuation is $20m but we’re on the doorstep of $8m in annual revenue...this is about the ratio (valuation of 2x annualized current revenue that I found myself in on P*TN back in October 2017 when I bought in at .06 and rode it to $1).
Do folks in the know agree with my logic here or am I missing something? Any other good info to add to the below?
FRLF INITIAL DD SUMMARY:
1) Key Shareholders
a. Clifford Perry (CEO, CFO, Director) = 48% of common stock
b. Richard Groberg (CFO) = 1.4m shares
c. Ray Medeiros (Director) = 2.7m shares
d. Paul Pelosi (Board Chair) = 5.1m shares
2) Business Lines — vertically integrated media and CBD product company
a. LaMarihuana.com and Marihuana-Medicinal.com — April 2017, Spanish speaking web portals
b. Leafceuticals Inc — began ops Jan 2018, hemp extraction business
c. Freedom Leaf International Inc. — no active operations
d. Irie CBD — hemp CBD product line
e. Hempology —CBD health/wellness brand
f. Valencia, Spain — hemp greenhouse
g. Plants to Paper — rolling paper company
h. Freedom Leaf Magazine — flagship publication
i. Tierra Science Global, LLC - 8/1/18, health supplements, $500k rev in 1st half of 2018 (manufacturing done by Irie) - est annual rev of $2.88m and 24% profit margin
j. Healthy Discovery Associates Corp - nutraceutical LDL Cholesterol inhibitor intellectual property acquisition
k. Green Market Europe - purchase that was cancelled on 6/4/18
3) Preferred Shares = 10m authorized, 1m is Series A convertible into 100 common per share
4) Revenues & Exp -
a. Reduction vs. 2017 is from moving away from licensing to product sales
b. $50k 3/31 quarter revenue from $30k CBD oil, $20k sale of product
c. Growth in G&A expense attributable in part to stock based compensation, non-cash expense
Amac1001
$MJ
